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METHODS: M-NCAS data were collected from nursing
staff ratings of nursing home patients diagnosed with
dementia (N = 281), in a randomized double-blind 
clinical trial comparing risperidone to placebo (RIS-AUS-
5 trial). For each item nurses rated the extent to which
they agree the target patient exhibits the behavior (agree,
partially agree, doubtful/unsure, don’t agree) and the
extent to which the behavior is difﬁcult to cope with (very
easy, easy, difﬁcult, very difﬁcult). Exploratory factor
analyses were performed separately for “agree” and
“cope” scales to determine if empirically and conceptu-
ally valid subscales exist. Internal consistency reliability
was assessed via Cronbach’s alpha. Correlations with the
BEHAVE-AD and Cohen-Mansﬁeld Agitation Inventory
were examined to evaluate construct validity.
RESULTS: Factor analysis resulted in identiﬁcation of 3
agree subscales (difﬁculty, attention seeking, autonomy)
and 5 cope subscales (predictability, self direction, need-
iness, job satisfaction, affect). Total scores were internally
consistent, with alphas of 0.74 for the agree scale and
0.95 for the cope scale. Internal consistency reliability
was also acceptable for the 3 agree subscales (0.69, 0.77,
0.57) and for the 5 cope subscales (0.89, 0.86, 0.83, 0.86,
0.79). The M-NCAS agree and cope total scale scores cor-
related most highly with the BEHAVE-AD aggressiveness
and anxiety/phobia subscales (r = 0.36, r = 0.35; r = 0.43,
r = 0.35 respectively: p < 0.001) and the CMAI
verbal/non-aggression and aggression subscales (r = 0.45,
r = 0.32; r = 0.34, r = 0.31, p < 0.001), indicating 
adequate construct validity.
CONCLUSIONS: The 32-item M-NCAS is an internally
consistent and valid scale for capturing both dementia-
speciﬁc behaviors and nursing perception of job burden
associated with those behaviors. The M-NCAS provides
detailed item-level as well as subscale-level data.
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LABOR SUPPLY OF POOR RESIDENTS IN
METROPOLITAN MIAMI:THE ROLE OF
DEPRESSION AND THE CO-MORBID EFFECTS
OF DRUG USE
Alexandre PK, French M
University of Miami, Miami, FL, USA
About 1 in every 20 employees experience depression in
the U.S. A recent study estimated that in 1990 the eco-
nomic costs of depression amounted to $43 billion, with
absenteeism alone contributing $12 billion.
OBJECTIVES: The study used 1996–1997 data col-
lected in crime-ridden and low-income neighborhoods of
Miami, Florida to 1) examine the relationship between
depression and employment; 2) conditional on being
employed, estimate the effect of depression on annual
weeks worked; 3) examine the robustness of the model
estimates to the co-morbid effects of drug use.
METHODS: The labor supply measures included
employment in past 30 days and number of weeks
worked in past 12 months. The analysis estimated a 
univariate probit model of employment as well as a
bivariate probit model of depression and employment,
which accounted for the possible correlation between the
unobserved determinants of depression and employment.
The annual weeks worked speciﬁcation was estimated by
a standard Tobit and an instrumental variable Tobit
model, which, besides the censoring of the observations,
accounted for the possible endogeneity of depression.
RESULTS: Results indicate that depressed individuals
had a 0.18 lower probability of employment relative to
non-depressed individuals in the univiariate probit model
and a 0.15 lower probability in the bivariate model. Both
standard and IV Tobit models found that depression 
signiﬁcantly reduced the number of annual weeks worked
by 8 weeks. Co-morbid drug use signiﬁcantly contributed
to the estimated effects of depression.
CONCLUSIONS: Prevention and/or treatment of mental
health problems such as depression may yield economic
beneﬁts by promoting employment and enhancing labor
supply. While expansion of mental health services may be
particularly beneﬁcial to the unemployed, employers may
ﬁnd it economically efﬁcient to allocate more resources
to stress management training and job redesign.
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TO ANTIDEPRESSANT PHARMACOTHERAPY
AMONG PATIENTS DIAGNOSED WITH
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OBJECTIVE: This study was designed 1) to investigate
the impact of primary payer type on access to antide-
pressant pharmacotherapy among patients diagnosed
with depression; 2) to identify predictors of antidepres-
sant pharmacotherapy, prescription for an SSRI or an
SNRI, and psychotherapy among patients diagnosed with
depression.
METHOD: Data from 1999 National Ambulatory
Medical Care Survey (NAMCS) was used for this analy-
sis. Odd ratios (OR) and 95% conﬁdence intervals (CI)
were used to investigate the impact of primary payer 
type on access to antidepressant pharmacotherapy and 
to elucidate the factors predictive of receipt of anti-
depressants, an SSRI or an SNRI and psychotherapy.
Model variables included age, gender, race, payer type,
region, metropolitan status, self-report depression as a
reason for the ofﬁce-based encounter, and duration of the
encounter.
RESULTS: Among estimated 19,445,888 patients 
diagnosed with depression in 1999, 74.0% were pre-
scribed with antidepressant pharmacotherapy, 56.7%
were prescribed an SSRI or SNRI and 40.8% received
psychotherapy. Medicaid beneﬁciaries (7.8%) were 70% 
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less likely to receive antidepressant pharmacotherapy
(OR = 0.30, 95% CI = 0.16–0.56) and 80% less likely to
receive an SSRI or SNRI (OR = 0.20, 95% CI =
0.10–0.40) but nearly twice more likely to receive psy-
chotherapy (OR = 2.93, 95% CI = 1.44–5.94), compared
to patients covered by private insurance (67.6%). Patients
lived in the south were the least likely to receive antide-
pressant pharmacotherapy, an SSRI or SNRI and psy-
chotherapy, compared to other regions (northeast, west
and midwest). Other factors predictive of receipt antide-
pressant pharmacotherapy include patients 50 to 64 years
old (patients 30 to 49 as reference) and female gender.
Other factor predictive of receipt of psychotherapy
included self-report depression as a reason for ofﬁce visit
and duration of the encounter.
CONCLUSION: Among patients diagnosed with depres-
sion, factors affecting the pattern of prescribing antide-
pressant pharmacotherapy and psychotherapy include 
a patient’s age, gender, type of insurance coverage, self-
report of depression and region lived in. Further research
is required to discern the reasons for these observed
effects.
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CLINICAL COMPARABILITY OF
SCHIZOPHRENIA PATIENTS SERVED AT TWO
PUBLIC SETTINGS: VETERANS AFFAIRS (VA)
AND NON-VA MEDICAID
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Differences between Veterans Affairs (VA) and non-VA
Medicaid patients with schizophrenia may limit the
ability to generalize study results from one group to the
other.
OBJECTIVE: This study assessed the clinical compara-
bility of patients with schizophrenia in these two popu-
lations (VA and Non-VA Medicaid), after adjusting for
important background characteristics.
METHOD: Baseline data from the U.S Schizophrenia
Care and Assessment Program, (US-SCAP), a prospective,
naturalistic study of schizophrenia, with a total of 223
VA patients were matched with Non-VA Medicaid
patients (N = 1,428), using propensity scores calculated
based on patients’ characteristics (gender, age, race, age
at illness onset, and study site). Using standard measures,
the matched pairs (N = 217) were compared on 28 
parameters of clinical symptomatology, level of function-
ing, quality of life, alcohol and drug abuse, depression,
concurrent medical conditions, prior hospitalization,
medication adherence, and work status.
RESULTS: VA and Non-VA Medicaid patients did not
signiﬁcantly differ on 26 of the 28 studied parameters.
For two-thirds of the parameters, the magnitude of the
difference between the groups was less than 10%.
CONCLUSIONS: Current ﬁndings suggest clinical com-
parability of VA and Non-VA Medicaid patient groups,
with potential generalizeability of clinical ﬁndings from
one group to the other, after adjustments for background
characteristics.
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